FDA ap­proves Roche’s sec­ond CD20xCD3 bis­pe­cif­ic in cer­tain lym­phomas

The FDA grant­ed ac­cel­er­at­ed ap­proval to Genen­tech’s CD20xCD3 bis­pe­cif­ic for pa­tients with a cer­tain type of non-Hodgkin’s lym­phoma on Thurs­day night, as the Roche unit and Gen­mab pro­mote dif­fer­ent ben­e­fits to their po­ten­tial­ly com­pet­i­tive med­i­cines.

Genen­tech’s Columvi and Ab­b­Vie/Gen­mab’s Ep­kin­ly, which was green­lit last month, are now ap­proved as third-line treat­ments for re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma, which is the most com­mon form of non-Hodgkin’s lym­phoma in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER